ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 482

Antibody Repertoire Sequencing, Antigen Array Analysis, and Cytokine Profiling of Blood from Individuals at High-risk for RA Reveals Candidate Immunoglobulin V Genes, ACPA, and Cytokines That May Promote the Transition to Arthritis

Radhika Iyer1, Amin Zia 1, Michelle Bloom 1, Sunil Nagpal 2, Navin Rao 2, Frédéric Baribaud 3, George Vratsanos 4, Wei Wang 5, Gary Firestein 6, David Boyle 5, Jane Buckner 7, V. Michael Holers 8, Kevin Deane 9 and William Robinson 10, 1Stanford University, Stanford, 2Janssen R&D, Spring House, PA, 3Janssen Research & Development, LLC, Spring House, PA, 4JNJ, Raritan, NJ, 5University of California, San Diego, San Diego, CA, 6University of California, San Diego, San Diego, 7Benaroya Research Institute, Seattle, WA, 8University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, 9University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, 10Stanford University, Stanford, CA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: anti-citrullinated protein/peptide antibodies (ACPA), Early Rheumatoid Arthritis, immunoglobulin (IG) and citrullination

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The “Targeting Immune Responses for Prevention of RA” (TIP-RA) collaboration studies individuals at high risk for developing rheumatoid arthritis (RA) because of serum anti-citrullinated protein antibody (ACPA) positivity in absence of arthritis at baseline, and is focused on defining how they transition from at-risk to classifiable disease. One potential mechanism is through the development, expansion and class-switching of B cells expressing pathogenic ACPA. Previous studies identified blood plasmablasts expressing ACPA in pre-clinical and established RA. Individuals enrolled in the TIP-RA cohort were analyzed by antibody repertoire sequencing, serum ACPA profiling, and serum cytokine analysis to identify features associated with progression to RA.

Methods: Cytokine array and ACPA array profiling were performed on serum samples from CCP- controls (n=156), (n-78), RA converters (n=3), and seropositive early-RA (n = 32). RNA was extracted from PAXgene whole blood tubes from CCP- (n=170), CCP3+ at risk (n=85), RA converters (n=3) and early RA individuals (n=41). Purified RNA was used for paired-end sequencing of immunoglobulin heavy-chain and run on a HiSeq 2500. Bulk IgH data was de-multiplexed with adapter sequences trimmed using MIGEC. Overlapping paired end reads were merged using MiTools. MIXCR was used to align sequencing reads to germline VDJ genes of B cell receptors obtained from IMGT, and subsequently group clones. VDJ gene family usage was analyzed using Alakazam (Immcantation).

Results: ACPA array analysis demonstrated development of ACPA targeting citrullinated fibrinogen and histone 2B as well as native vimentin as associated with transition to clinical arthritis.  Cytokine profiling revealed increased levels of multiple pro-inflammatory cytokines and chemokines in the blood. Immunoglobulin heavy chain sequencing identified persistent clones (based on shared V and J gene usage, identical CDR3 lengths, and >60% amino acid homology) that underwent both expansion and class switching to IgA and IgG. Specifically, we identified clones encoding IgH-V3-23/IgHJ4 and IgHV1-2/IgHJ4 that switched and expanded from IgM pre-conversion to IgA and IgG isotypes post-conversion to RA (Figure 1).

Conclusion: Asymptomatic anti-CCP+ individuals that converted to RA exhibited increased levels of blood cytokines and ACPA. These individuals also exhibited expression, expansion and class-switching of B cell clones encoding IgH-V3-23/IgHJ4 and IgHV1-2/IgHJ4, antibody V genes previously identified as being expressed by RA plasmablasts and encoding anti-citrullinated protein antibodies (ACPA).  IgH-V3-23/IgHJ4 and IgHV1-2/IgHJ4 may encode ACPA that promote the transition to clinical RA, and further investigation is needed to fully define their citrullinated antigen targets and potential role in promoting the transition to clinical RA.


Figure 1 edit

B cell clones encoding IgH-V3-23/IgHJ4 and IgHV1-2/IgHJ4 class switch from IgM pre-conversion to IgA and IgG isotypes post-conversion in TIP-RA converters.


Disclosure: R. Iyer, None; A. Zia, None; M. Bloom, None; S. Nagpal, Janssen Research & Development, 3, Janssen Research, Johnson&Johnson, 1, 3, 4, Johnson & Johnson, 1, 4; N. Rao, Janssen Research & Development, 3, Johnson & Johnson, 1, 3, 4; F. Baribaud, Janssen Research & Development, LLC, 3; G. Vratsanos, Janssen Research & Development, 1, 3; W. Wang, None; G. Firestein, Abbvie, 2, Janssen, 2; D. Boyle, Janssen, 2; J. Buckner, Bristol-Myers Squibb, 2, 5, Eli Lilly, 5, Janssen, 2, Novo Nordisk, 2, Pfizer, 2; V. Holers, AdMIRx, 1, 2, 4, 5, 6, Alexion, 7, BMS, 5, Bristol-Myers Squibb, 5, Celgene, 5, Janssen R&D, 2, 5, Pfizer, 2; K. Deane, Bristol-Myers Squibb, 5, Inova, 9, Janssen, 2, 5, Janssen R&D, 2, Microdrop, 5, Pfizer, 2; W. Robinson, None.

To cite this abstract in AMA style:

Iyer R, Zia A, Bloom M, Nagpal S, Rao N, Baribaud F, Vratsanos G, Wang W, Firestein G, Boyle D, Buckner J, Holers V, Deane K, Robinson W. Antibody Repertoire Sequencing, Antigen Array Analysis, and Cytokine Profiling of Blood from Individuals at High-risk for RA Reveals Candidate Immunoglobulin V Genes, ACPA, and Cytokines That May Promote the Transition to Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/antibody-repertoire-sequencing-antigen-array-analysis-and-cytokine-profiling-of-blood-from-individuals-at-high-risk-for-ra-reveals-candidate-immunoglobulin-v-genes-acpa-and-cytokines-that-may-prom/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antibody-repertoire-sequencing-antigen-array-analysis-and-cytokine-profiling-of-blood-from-individuals-at-high-risk-for-ra-reveals-candidate-immunoglobulin-v-genes-acpa-and-cytokines-that-may-prom/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology